Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Exp Neurol. 2013 Jun 26;248:228–235. doi: 10.1016/j.expneurol.2013.06.020

Figure 2. Tat 1–101C and Tat 1–86 (Cys22) do not produce synaptodendritic injury.

Figure 2

A. Tat 1–86 (Cys22) or Tat 1–101 Clade C treatment (50nM) for 24 hours did not produce significant loss of F-actin puncta relative to controls. Second order dendritic branches were selected from 20X images of F-actin/MAP2/Hoechst-stained Tat-treated and non-treated control pyramidal hippocampal neurons for puncta quantification. Results are presented as mean F-actin labeled puncta per 10µm of neuronal dendrite ± SEM.

B. Tat 1–101 Clade C or Tat 1–86 (Cys22) treatment (50nM) for 48 hours did not produce cell death. Fluorescent units were determined in hippocampal cell cultures using Live/Dead assays. Results are presented as mean values ± SEM.

C. Control, Tat 1–86 (Cys22) (50nM) and Tat 1–101 Clade C (50nM) treated neurons labeled with F-actin(Green)/MAP-2(Red)/Hoescht(Blue). The hippocampal pyramidal neuron in the control condition demonstrates robust F-actin labeling (green), complex branching patterns, with extensive fine dendritic network. Tat 1–86 (Cys22) and 1–101 Clade C neurons also presented strong F-actin labeling and complex dendritic branching patterns, suggesting that treatment with these peptides does not produce significant changes in dendritic integrity. Scale bar = 50 microns